Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03427814 · ClinicalTrials.gov registry record · Phase 2
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
A Phase 2 study of Advanced or Inoperable Gastric Cancer, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 20
- Study locations
NCT03427814: Completed Phase 2 study of Advanced or Inoperable Gastric Cancer, sponsored by BeiGene.
NCT03427814 is a Phase 2 study of Advanced or Inoperable Gastric Cancer that has completed, run by BeiGene. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03427814, a Phase 2 study of Advanced or Inoperable Gastric Cancer, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.
Primary Outcome
PFS is defined as the time from randomization to progressive disease (PD) per Response Evaluation Criteria in Solid Tumors ( RECIST) Version 1.1 by investigator assessment or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pamiparib
Study Locations (20)
Guangdong
- Sun Yat Sen University Cancer Center - Guangzhou
- Nanfang Hospital of Southern Medical University - Guangzhou
- Cancer Hospital of Shantou University Medical College - Shantou
Florida
- Miami Cancer Institute - Miami
- Scri Florida Cancer Specialist East - West Palm Beach
Victoria
- Monash Health - Clayton
- Ballarat Oncology and Haematology Services - Wendouree
Other
- Az Sint Jan Brugge - Bruges
- University Hospitals Leuven - Leuven
Indiana
- Goshen Center For Cancer Care - Goshen
Kansas
- Cancer Center of Kansas - Wichita
Kentucky
- Norton Cancer Institute - Louisville
North Carolina
- Novant Health Hematology Charlotte - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2018-07-03 |
| Est. Completion | 2023-01-03 |
| Phase | Phase 2 |
What the finished NCT03427814 record still lists
NCT03427814 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Advanced or Inoperable Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03427814 names 20 study sites across 15 states, led by Guangdong, Florida, Victoria.
Frequently Asked Questions
What is clinical trial NCT03427814 about?
NCT03427814 is a clinical study titled "Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer". This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 ...
What is the current status of trial NCT03427814?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2018-07-03. Estimated completion is 2023-01-03.
What conditions does trial NCT03427814 study?
This clinical trial studies the following conditions: Advanced or Inoperable Gastric Cancer.
What interventions are being tested in trial NCT03427814?
The interventions under investigation include: Placebo (DRUG), Pamiparib (DRUG).
Who is sponsoring clinical trial NCT03427814?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03427814 being conducted?
This trial has 20 study locations across Florida, Indiana, Kansas, Kentucky, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03427814's enrollment target sits among peer trials
136 527th of 2000 higher than 1,469 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI